Leah Croll, MD, Assistant Professor of Clinical Neurology at the Lewis Katz School of Medicine at Temple University, offered insight to ABC News on the U.S. Food and Drug Administration (FDA) granting accelerated approval to Leqembi, which showed in a large study that it could slow the rate of cognitive decline in people with the early stages of Alzheimer’s disease.
Weather Alert: Temple Health remains open, though some appointments or services may be adjusted. Patients will be contacted directly if their visit is affected. Please check TempleHealth.org for updates and monitor myTempleHealth for changes to scheduled appointments.
800-TEMPLE-MED
Schedule Appointment
SEARCH TEMPLE HEALTH